That means that even with an obesity diagnosis and a prescription, people will have to pay for the GLP-1 out of pocket
"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS Journal , 2024
Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration
Important Note on the Evidence Base Important note on the evidence base: The published research on BPC-157 consists predominantly of animal-model studies (primarily rats) and in vitro cell-culture experiments
